SymBio Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

SymBio Pharmaceuticals şirketinin toplam hissedar öz sermayesi ¥5.2B ve toplam borcu ¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥6.1B ve ¥910.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

JP¥0

Borç

Faiz karşılama oranı	n/a
Nakit	JP¥5.13b
Eşitlik	JP¥5.16b
Toplam yükümlülükler	JP¥910.31m
Toplam varlıklar	JP¥6.07b

Son finansal sağlık güncellemeleri

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

Sep 24

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Feb 09

Recent updates

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

Sep 24

SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up

Aug 06

Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge

Jun 11

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Feb 09

If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

Dec 18

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4582 'nin kısa vadeli varlıkları ( ¥6.0B ) kısa vadeli yükümlülüklerini ( ¥906.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4582 şirketinin kısa vadeli varlıkları ( ¥6.0B ) uzun vadeli yükümlülüklerini ( ¥4.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4582 borçsuzdur.

Borcun Azaltılması: 4582 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 4582 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 4582 serbest nakit akışı her yıl % 34.4 oranında tarihsel oranda büyümeye devam ederse 3 yıldan fazla bir süre için yeterli nakit akışına sahip olur

SymBio Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

SymBio Pharmaceuticals ADR - Sponsored to Be Deleted from OTC Equity

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Recent updates

Third quarter 2024 earnings released: JP¥28.45 loss per share (vs JP¥17.83 loss in 3Q 2023)

SymBio Pharmaceuticals Limited to Report Q3, 2024 Results on Oct 31, 2024

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up

Second quarter 2024 earnings released: JP¥16.75 loss per share (vs JP¥2.09 loss in 2Q 2023)

SymBio Pharmaceuticals Limited to Report Q2, 2024 Results on Aug 01, 2024

Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge

New major risk - Share price stability

First quarter 2024 earnings released: JP¥18.02 loss per share (vs JP¥0.10 profit in 1Q 2023)

Full year 2023 earnings released: JP¥49.17 loss per share (vs JP¥30.20 profit in FY 2022)

SymBio Pharmaceuticals Limited announced that it has received ¥256.5 million in funding from Evolution Capital Management LLC

Full year 2023 earnings released

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 22, 2024

SymBio Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 08, 2024

Third quarter 2023 earnings released

SymBio Pharmaceuticals Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released

SymBio Pharmaceuticals Limited to Report Q2, 2023 Results on Aug 03, 2023

New minor risk - Share price stability

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 26%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 23, 2023

SymBio Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Feb 09, 2023

Third quarter 2022 earnings released: EPS: JP¥11.32 (vs JP¥13.83 in 3Q 2021)

Symbio Pharmaceuticals Limited Revises Earnings Forecast for the Period from January 1, 2022 to December 31, 2022

SymBio Pharmaceuticals Limited to Report Q3, 2022 Results on Nov 08, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: JP¥24.36 (vs JP¥0.11 in 2Q 2021)

Symbio Pharmaceuticals Limited Revises Earning Guidance for Fiscal Year Ending December 31, 2022

SymBio Pharmaceuticals ADR - Sponsored to Be Deleted from OTC Equity

SymBio Pharmaceuticals Limited to Report Q2, 2022 Results on Aug 04, 2022

SymBio Pharmaceuticals Limited announced that it has received ¥675.76 million in funding from CVI Investments, Inc.

Investor sentiment improved over the past week

SymBio Pharmaceuticals Limited announced that it expects to receive ¥675.76 million in funding from CVI Investments, Inc.

First quarter 2022 earnings released: EPS: JP¥4.25 (vs JP¥5.47 loss in 1Q 2021)

SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Less than half of directors are independent

SymBio Pharmaceuticals Limited to Report Q1, 2022 Results on May 11, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Third quarter 2021 earnings released: EPS JP¥13.79 (vs JP¥23.01 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥0.10 (vs JP¥27.30 loss in 2Q 2020)

First quarter 2021 earnings released

Full year 2020 earnings released: JP¥124 loss per share (vs JP¥189 loss in FY 2019)

SymBio Pharmaceuticals Limited to Report Q1, 2021 Results on May 13, 2021

New 90-day high: JP¥1,380

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Full year 2020 earnings released: JP¥124 loss per share (vs JP¥189 loss in FY 2019)

New 90-day high: JP¥895

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 24, 2021

New 90-day low: JP¥337

If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

Third quarter 2020 earnings released: JP¥23.01 loss per share

New 90-day low: JP¥379

Symbio Pharmaceuticals Limited Receives Approval of TREAKISYM Ready-To-Dilute ('Rtd') Formulation, with Launch Expected in January 2021

New 90-day low - JP¥409

Earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin